Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report

OBJECTIVE: ROS1 fusions have been identified in 1–2% of non-small-cell lung cancer (NSCLC) patients; they are validated as a driver of carcinogenesis and could be subjected to inhibition by crizotinib. However, previous studies suggested a variable progression-free survival (PFS) ranging from 9.1 to...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Onco Targets Ther
Autors principals: Shu, Yun, Li, Hui, Shang, Hongjuan, Chen, Jun, Su, Xiaoxing, Le, Wei, Lei, Yan, Tao, Liming, Zou, Cailiang, Wu, Wendy
Format: Artigo
Idioma:Inglês
Publicat: Dove 2020
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7568639/
https://ncbi.nlm.nih.gov/pubmed/33116618
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S270961
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars